| Yevgeniy Latyshev, MD | |
|
62 Ridge Rd, North Arlington, NJ 07031-6318 | |
| (201) 351-0677 | |
| Not Available |
| Full Name | Yevgeniy Latyshev |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 14 Years |
| Location | 62 Ridge Rd, North Arlington, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225342439 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 25MA10264000 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jersey Shore University Medical Center | Neptune, NJ | Hospital |
| Jfk Medical Center | Edison, NJ | Hospital |
| Raritan Bay Medical Center Perth Amboy Division | Perth amboy, NJ | Hospital |
| Robert Wood Johnson University Hospital | New brunswick, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hackensack Meridian Health Medical Group - Specialty Care Pc | 9133032519 | 1090 |
News Archive
The National Patient Safety Foundation, a nonprofit specializing in advancing safe patient care, is creating a groundbreaking new membership program for patient safety professionals that will provide a unique opportunity for sharing of best practices and the unification of the growing patient safety community. New members can join the American Society of Professionals in Patient Safety at NPSF starting in January 2011.
Developed by biomedical engineers at the University of Limerick the device will improve success rates in angioplasty procedures. It is estimated that over 1 million angioplasty procedures are undertaken worldwide each year and the value of products relating to this procedure is in the region of €500million.
In a new study, Tel Aviv University researchers reveal how they invented the first fully personalized tissue implant, engineered from a patient's own materials and cells. The new technology makes it possible to engineer any kind of tissue implant from one small fatty tissue biopsy.
ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia.
› Verified 1 days ago
| Entity Name | Hackensack Meridian Health Medical Group - Specialty Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215989249 PECOS PAC ID: 9133032519 Enrollment ID: O20031111000524 |
News Archive
The National Patient Safety Foundation, a nonprofit specializing in advancing safe patient care, is creating a groundbreaking new membership program for patient safety professionals that will provide a unique opportunity for sharing of best practices and the unification of the growing patient safety community. New members can join the American Society of Professionals in Patient Safety at NPSF starting in January 2011.
Developed by biomedical engineers at the University of Limerick the device will improve success rates in angioplasty procedures. It is estimated that over 1 million angioplasty procedures are undertaken worldwide each year and the value of products relating to this procedure is in the region of €500million.
In a new study, Tel Aviv University researchers reveal how they invented the first fully personalized tissue implant, engineered from a patient's own materials and cells. The new technology makes it possible to engineer any kind of tissue implant from one small fatty tissue biopsy.
ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia.
› Verified 1 days ago
| Entity Name | Meridian Medical Group-specialty Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942362587 PECOS PAC ID: 6507962206 Enrollment ID: O20070425000673 |
News Archive
The National Patient Safety Foundation, a nonprofit specializing in advancing safe patient care, is creating a groundbreaking new membership program for patient safety professionals that will provide a unique opportunity for sharing of best practices and the unification of the growing patient safety community. New members can join the American Society of Professionals in Patient Safety at NPSF starting in January 2011.
Developed by biomedical engineers at the University of Limerick the device will improve success rates in angioplasty procedures. It is estimated that over 1 million angioplasty procedures are undertaken worldwide each year and the value of products relating to this procedure is in the region of €500million.
In a new study, Tel Aviv University researchers reveal how they invented the first fully personalized tissue implant, engineered from a patient's own materials and cells. The new technology makes it possible to engineer any kind of tissue implant from one small fatty tissue biopsy.
ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia.
› Verified 1 days ago
| Entity Name | Optum Medical Care Of New Jersey Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578665048 PECOS PAC ID: 3072650290 Enrollment ID: O20091021000129 |
News Archive
The National Patient Safety Foundation, a nonprofit specializing in advancing safe patient care, is creating a groundbreaking new membership program for patient safety professionals that will provide a unique opportunity for sharing of best practices and the unification of the growing patient safety community. New members can join the American Society of Professionals in Patient Safety at NPSF starting in January 2011.
Developed by biomedical engineers at the University of Limerick the device will improve success rates in angioplasty procedures. It is estimated that over 1 million angioplasty procedures are undertaken worldwide each year and the value of products relating to this procedure is in the region of €500million.
In a new study, Tel Aviv University researchers reveal how they invented the first fully personalized tissue implant, engineered from a patient's own materials and cells. The new technology makes it possible to engineer any kind of tissue implant from one small fatty tissue biopsy.
ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Yevgeniy Latyshev, MD 62 Ridge Rd, North Arlington, NJ 07031-6318 Ph: () - | Yevgeniy Latyshev, MD 62 Ridge Rd, North Arlington, NJ 07031-6318 Ph: (201) 351-0677 |
News Archive
The National Patient Safety Foundation, a nonprofit specializing in advancing safe patient care, is creating a groundbreaking new membership program for patient safety professionals that will provide a unique opportunity for sharing of best practices and the unification of the growing patient safety community. New members can join the American Society of Professionals in Patient Safety at NPSF starting in January 2011.
Developed by biomedical engineers at the University of Limerick the device will improve success rates in angioplasty procedures. It is estimated that over 1 million angioplasty procedures are undertaken worldwide each year and the value of products relating to this procedure is in the region of €500million.
In a new study, Tel Aviv University researchers reveal how they invented the first fully personalized tissue implant, engineered from a patient's own materials and cells. The new technology makes it possible to engineer any kind of tissue implant from one small fatty tissue biopsy.
ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia.
› Verified 1 days ago
Dr. Andrew E Burachinsky, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 62 Ridge Rd, North Arlington, NJ 07031 Phone: 201-991-8565 Fax: 201-991-2408 | |
Dr. Sheremet Gashi, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 11 Ridge Rd, North Arlington, NJ 07031 Phone: 201-998-1800 Fax: 201-998-1891 | |
Dr. Frank T Barbera, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 68 Ridge Rd, North Arlington, NJ 07031 Phone: 201-998-7333 Fax: 201-998-5715 | |
Ammar Haikal, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 312 Belleville Tpke Ste 3a, North Arlington, NJ 07031 Phone: 201-998-2800 Fax: 201-998-0800 | |
Dr. Athos C Anastasiades, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 62 Ridge Rd, North Arlington, NJ 07031 Phone: 201-991-8565 Fax: 201-991-2408 | |
Dr. Michael Guma, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 312 Belleville Tpke, Suite 3a, North Arlington, NJ 07031 Phone: 201-998-2800 Fax: 201-998-0800 |